Investment Analysts’ Recent Ratings Changes for Attovia Therapeutics (ATTO)

A number of research firms have changed their ratings and price targets for Attovia Therapeutics (NASDAQ: ATTO):

• 9/4/2026 – Attovia Therapeutics was upgraded by Zacks Research to “hold”.
• 8/31/2026 – Attovia Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $45.00 price target on the stock.
• 8/31/2026 – Attovia Therapeutics is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $45.00 price target on the stock.
• 8/31/2026 – Attovia Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $30.00 price target on the stock.
• 8/31/2026 – Attovia Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $52.00 price target on the stock.
• 8/31/2026 – Attovia Therapeutics is now covered by Morgan Stanley. They set an “overweight” rating and a $39.00 price target on the stock.
• 8/30/2026 – Attovia Therapeutics was upgraded by Royal Bank Of Canada to “moderate buy”.

Insider Buying and Selling at Attovia Therapeutics

In other Attovia Therapeutics news, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the acquisition, the insider directly owned 6,154,213 shares of the company’s stock, valued at approximately $104,621,621. This trade represents a 10.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Colin Walsh acquired 500,000 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the transaction, the director owned 3,020,632 shares in the company, valued at approximately $51,350,744. The trade was a 19.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 2,740,587 shares of company stock worth $47,269,979 over the last 90 days.

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company.